Dr. Reddy's Laboratories announces the launch ofTobramycin Inhalation Solution, USPin the U.S. Market

Hyderabad, India, June 25, 2019For Immediate Release

…..….…………………………………………………………………………………………………………………………………………………………………...

Hyderabad, India and Princeton, NJ, USA. June 25,2019—Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch ofTobramycin Inhalation Solution, USPa therapeutic equivalent generic version ofTOBI® (tobramycin) Inhalation Solution,approved by the U.S. Food and Drug Administration (USFDA). 

The TOBI® (tobramycin) Inhalation Solutionbrand and generic had U.S. sales of approximately $97million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.

Dr. Reddy’s Tobramycin Inhalation Solution, USP is available in a 300 mg/5 mL, single-dose Ampule.

Tobi® is a trademark of Mylan.

*IQVIA Retail and Non-Retail MAT April2019.

RDY-0619-250

……………………………………………………………………………………..……………………………………………………………………………………………………………………..……………….

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to:www.drreddys.com

……………………………………………………………………………………………………………………………………………………………………..

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to  without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.